SBIR Topic 255: Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an

大多数死于癌症的患者死于晚期转移性癌症。这些患者通常是治疗难治性的，并且构成了癌症最大的未开发市场。我们已经开发了一种独特有效的基于抗PECAM-1单克隆抗体（mAb）的疗法。据我们所知，这种mAb是唯一一种安全有效治疗晚期肿瘤转移的治疗方法，与肿瘤类型无关。抗PECAM-1 mAb治疗的临床转化可能会彻底改变这种目前难治性临床实体的治疗。因此，我们建议进行以下临床前研究，以将基于抗PECAM- 1 mAb的治疗转化为癌症患者的I期临床试验。

Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.